Transforming Our Discoveries into Therapeutics

 

AeolusAeolus Pharmaceuticals is developing AEOL 10150, a small molecule catalytic antioxidant that has shown the ability to scavenge a broad range of reactive oxygen species. AEOL 10150 is currently undergoing human clinical evaluation in patients with ALS. James Crapo, MD, and Brian Day, PhD, of National Jewish Health are inventors on the intellectual property underlying this discovery.
  
ArthroVentions LogoArthroventions is a Colorado LLC developing a family of devices that distend the synovial fluid to improve the accuracy of aspirating and injecting medication into the joint space. Joint taps for the treatment of arthritis are common, out-patient procedures. However, these procedures can be painful, inconvenient, and ineffective if the joint space if missed. Based on the work from Dr. Richard Meehan, MD at National Jewish Health, Arthroventions developed a medical device, The KneeTap™, which simplifies precision injections and ensures that pain relieving therapies are delivered accurately and safely. The simple design allows for medial or lateral approaches without increasing procedure time or requiring additional training. The KneeTap™ is the flagship product for Arthroventions. The patented technology can be utilized for all joints and is also available for veterinary applications.
  
JuvarisJuvaris BioTherapeutics was founded in 2003, based on the intellectual property developed at National Jewish Health by Steven Dow, DVM, PhD. Juvaris BioTherapeutics is developing therapeutic vaccines for cancer and infectious diseases using its novel technology platform of cationic lipids and non-coding DNA complexes.
  
OncoMatryx LogoOncomatrix was founded in 2010 by a group of Spanish, British, and French entrepreneurs with extensive experience in the biotechnology industry. Oncomatrix is developing innovative treatments that target the tumor connection to the surrounding stroma: a cancer treatment aimed at attacking not tumor cells, but the peritumoral cells and extracellular matrix that facilitate tumor invasiveness and resistance. Oncomatrix is developing a cystatin-c related drug candidate based on a research discovery from scientist Dr. William Schiemann, PhD at National Jewish Health. This strategy targets the TGF-beta signaling and aims at inhibit cancer progression and improving the prognosis and treatment of cancer patients.
  

OrPro Logo

OrPro Therapeutics, Inc. is a pre-clinical stage biopharmaceutical company headquartered in San Diego, CA. The company's goal is to develop a breakthrough class of safe, well-tolerated and more effective inhaled non-systemic drugs based on the thioredoxin active site for the treatment of patients with cystic fibrosis (CF), COPD/emphysema, bronchiectasis, severe asthma, and other serious obstructive pulmonary diseases. OrPro's lead product, ORP-100, an aerosolized variant of recombinant human thioredoxin, will target abnormal viscosity due to excess protein gels in CF and has the potential for broader clinical efficacy than existing mucolytic approaches. OrPro is the exclusive licensee of intellectual property relating to the thioredoxin active site developed by pediatric pulmonologist Dr. Carl White, MD at National Jewish Health.
   
Taiga LogoTaiga Biotechnologies was founded to develop novel approaches to treat hematological diseases, including cancers, immunodeficiencies and autoimmune conditions. Their three-pronged approach combines novel breakthroughs by Yosef Refaeli, PhD, John Cambier, PhD, and colleagues at National Jewish Health and University of Colorado Denver in cellular, biologic and small molecule approaches to treat and manage these diseases.
   
TaligenTaligen Therapeutics, Inc., which was founded in March 2004 by Drs. Woody Emlen and V. Michael Holers, is working to develop and commercialize technologies created by scientists from National Jewish Health (Erwin Gelfand, MD) and the University of Colorado Denver. Taligen is a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease. The Company employs novel technologies designed to modulate and regulate activation of the complement system.
  
vistagenVistaGen applies their innovative in vitro embryonic stem (ES) cell technologies to discover and develop new generation drugs and protein biologics, both internally and through strategic collaborations with the pharmaceutical and biotechnology industries. Vistagen's clinically predictive in vitro embryonic stem cell technologies are based on intellectual property developed at National Jewish Health by Gordon Keller, PhD.




For more information, contact Emmanuel Hilaire at HilaireE@njhealth.org

Bookmark and Share

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our Faculty by Area of Research.